Chongqing Genrix Biopharmaceutical (SH:688443) Huan Qiu Wang·2025-12-07 12:33Group 1 - The National Healthcare Security Administration officially announced the inclusion of ZhiXiang JinTai's innovative drug, Saliqi monoclonal antibody injection (JinLiXi®), in the National Medical Insurance Catalog, effective January 1, 2026 [1] - ZhiXiang JinTai focuses on the research and industrialization of antibody drugs, emphasizing technological innovation to meet significant clinical needs and provide affordable treatment options [2] - Saliqi monoclonal antibody is China's first fully human anti-IL-17A monoclonal antibody, developed using a unique phage display technology platform, breaking the monopoly of foreign pharmaceutical companies in this treatment area [2] Group 2 - Clinical studies demonstrate the efficacy of Saliqi monoclonal antibody in treating moderate to severe plaque psoriasis and ankylosing spondylitis, with a PASI75 response rate of 90.7% at week 12 and a sustained PASI75 response rate of 96.5% at week 52 [3] - The drug has shown significant improvement in patients with ankylosing spondylitis, with ASAS 20 response rates of 74.0% and 65.8% for different dosages, outperforming the placebo group [3] - The inclusion of Saliqi monoclonal antibody in the National Medical Insurance Catalog is seen as a recognition of the value of domestic innovative drugs and a milestone in the company's development [4] Group 3 - ZhiXiang JinTai has already achieved market coverage in 30 provinces, benefiting over 10,000 patients in China, and the inclusion in the insurance catalog will further reduce out-of-pocket expenses for patients [4] - The company aims to continue developing internationally competitive innovative drugs and to ensure that high-quality treatments are accessible to more patients and families in China [4]